Skip to Content

Immunomedics to Present At American Society of Hematology 49th Annual Meeting

MORRIS PLAINS, N.J., Dec. 3, 2007 (PRIME NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that four presentations will be given at the 49th Annual Meeting of the American Society of Hematology (ASH), scheduled for December 8 - 11, 2007, in Atlanta, Georgia. The schedule and meeting places for the poster sessions, together with the abstract and board numbers are listed below:

* "Improved Therapy of Multiple Myeloma by Combining Milatuzumab (Anti-CD74 Humanized mAb) and Bortezomib: In Vitro and In Vivo Results" (Publication No. 1176, Session Name: Experimental Therapies for Multiple Myeloma, Saturday, December 8, 9:00 a.m. - 7:30 p.m., Board #330, Hall B3 and B4)

* "A New Class of Dimeric a-interferons (IFN-a) Made by the Dock and Lock (DNL) Method for Improved Cancer Therapy" (Publication No. 1396, Session Name: Lymphoma: Pre-Clinical: Chemotherapy and Biologic Agents I, Saturday, December 8, 9:00 a.m. - 7:30 p.m., Board #550, Hall B3 and B4)

* "Improved Responses and Cures with Less Hematologic Toxicity Using Anti-CD20 Bispecific Antibody Pretargeted Radionuclides Compared to Directly Radiolabeled IgG in a NHL Model" (Publication No. 2344, Session Name: Lymphoma: Pre-Clinical: Chemotherapy and Biologic Agents II, Sunday, December 9, 9:00 a.m. - 8:00 p.m., Board #534, Hall B3 and B4)

* "Durable Complete Responses Following Therapy with Epratuzumab Plus Rituximab: Final Efficacy Results of a Multicenter Study in Recurrent Indolent Non-Hodgkin's Lymphoma (NHL)" (Publication No. 3419, Session Name: Immunotherapy for Lymphoma, including Radio-Immunotherapy, Monday, December 10, 10:30 a.m. - 7:00 p.m., Board #638, Hall B3 and B4)

About Immunomedics

Immunomedics is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We have exclusively licensed our lead product candidate, epratuzumab, to UCB ( for the treatment of all autoimmune disease indications worldwide. Epratuzumab's most advanced program is for the treatment of systemic lupus erythematosus (SLE). At present, there is no cure for lupus and no new lupus drug has been approved in the U.S. in the last 40 years. We have retained the rights for epratuzumab in oncology indications for which UCB has been granted a buy-in option. The Company is conducting clinical trials with veltuzumab in patients with non-Hodgkin's lymphoma, epratuzumab as a potential therapeutic for patients with lymphoma and leukemia, 90Y-epratuzumab for the therapy of patients with lymphoma, 90Y-hPAM4 for pancreas cancer therapy and milatuzumab as a therapy for patients with multiple myeloma. We believe that our portfolio of intellectual property, which includes approximately 108 patents issued in the United States, and more than 250 other issued patents worldwide, protects our product candidates and technologies. We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel Dock-and-Lock (DNL) methodology, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. For additional information on us, please visit our web site at The information on our website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on our licensing partner for the further development of epratuzumab for autoimmune indications, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

-0- CONTACT: Immunomedics, Inc. Dr. Chau Cheng, Associate Director, Investor Relations and Business Analysis (973) 605-8200, ext. 123



Posted: December 2007